Immune checkpoint blockade and interferon-α in melanoma

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 436-447

  Rafique, Imran ^a   Kirkwood, John M ^a   Tarhini, Ahmad A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; LYMPHOCYTE ANTIGEN; PROGRAMMED CELL DEATH 1; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ANTIGEN PRESENTATION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; TUMOR ESCAPE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MELANOMA; TUMOR ESCAPE;

EID: 84929163697     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.012     Document Type: Review

References (95)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. SEER Cancer Statistics Review, 1975 2009 (Vintage 2009 Populations [http://seercancergov/csr/1975-2009-pops09/ (based on November 2011 SEER datasubmission, posted to the SEER wevsite April 2012.]
3. A.A. Tarhini, and J.M. Kirkwood Clinical and immunologic basis of interferon therapy in melanoma Ann N Y Acad Sci 1182 2009 47 57
4. S.V. Kotenko, G. Gallagher, and V.V. Baurin IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 2003 69 77
5. P. Sheppard, W. Kindsvogel, and W. Xu IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68
6. T.R. O'Brien Interferon-alfa, interferon-lambda and hepatitis C Nat Genet 41 2009 1048 1050
7. L.C. Platanias Mechanisms of type-I- and type-II-interferon-mediated signalling Nat Rev Immunol 5 2005 375 386
8. J.M. Kirkwood, T. Richards, and H.M. Zarour Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 Cancer 95 2002 1101 1112
9. W. Wang, H.D. Edington, and U.N. Rao Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b Clin Cancer Res 13 2007 1523 1531
10. R.L. Paquette Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells J Leukoc Biol 64 1998 358 367
11. S. Parlato, S.M. Santini, and C. Lapenta Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities Blood 98 2001 3022 3029
12. V. Brinkmann, T. Geiger, S. Alkan, and C.H. Heusser Interferon alpha increases the frequency of interferon gamma-producing human CD4+T cells J Exp Med 178 1993 1655 1663
13. C.A. Wenner, M.L. Guler, S.E. Macatonia, A. O'Garra, and K.M. Murphy Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development J Immunol 156 1996 1442 1447
14. L. Rogge, L. Barberis-Maino, and M. Biffi Selective expression of an interleukin-12 receptor component by human T helper 1 cells J Exp Med 185 1997 825 831
15. K.J. Palmer, M. Harries, M.E. Gore, and M.K. Collins Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC) Clin Exp Immunol 119 2000 412 418
16. Z.R. Yurkovetsky, J.M. Kirkwood, and H.D. Edington Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b Clin Cancer Res 13 2007 2422 2428
17. D.F. Tough Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation Leuk Lymphoma 45 2004 257 264
18. S.J. Moschos, H.D. Edington, and S.R. Land Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 2006 3164 3171
19. M.B. Fuertes, A.K. Kacha, and J. Kline Host type I IFN signals are required for antitumor CD8+T cell responses through CD8{alpha}+dendritic cells J Exp Med 208 2011 2005 2016
20. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684 J Clin Oncol 14 1996 7 17
21. J.M. Kirkwood, J.G. Ibrahim, and V.K. Sondak High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444 2458
22. J.M. Kirkwood, J.G. Ibrahim, and J.A. Sosman High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2001 2370 2380
23. J.M. Kirkwood, J. Ibrahim, and D.H. Lawson High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696 J Clin Oncol 19 2001 1430 1436
24. A.M. Eggermont, S. Suciu, and A. Testori Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 2012 3810 3818
25. P.S. Linsley, J. Bradshaw, J. Greene, R. Peach, K.L. Bennett, and R.S. Mittler Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement Immunity 4 1996 535 543
26. K.S. Peggs, S.A. Quezada, A.J. Korman, and J.P. Allison Principles and use of anti-CTLA-4 antibody in human cancer immunotherapy Curr Opin Immunol 18 2006 206 213
27. C. Robert, and F. Ghiringhelli What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14 2009 848 861
28. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
29. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
30. A. Ribas, A. Hauschild, and R. Kefford Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma J Clin Oncol 26 Suppl 2008 abstract LBA9011
31. L. Chen Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity Nat Rev Immunol 4 2004 336 347
32. G.J. Freeman, A.J. Long, and Y. Iwai Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
33. T. Okazaki, Y. Iwai, and T. Honjo New regulatory co-receptors: inducible co-stimulator and PD-1 Curr Opin Immunol 14 2002 779 782
34. A.H. Sharpe, E.J. Wherry, R. Ahmed, and G.J. Freeman The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection Nat Immunol 8 2007 239 245
35. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
36. S.Y. Tseng, M. Otsuji, and K. Gorski B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 846
37. Y. Latchman, C.R. Wood, and T. Chernova PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
38. C. Blank, I. Brown, and A.C. Peterson PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+T cells Cancer Res 64 2004 1140 1145
39. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
40. T.F. Gajewski Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment Clin Cancer Res 12 2006 2326s 2330s
41. J. Hamanishi, M. Mandai, and M. Iwasaki Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 2007 3360 3365
42. R.H. Thompson, S.M. Kuntz, and B.C. Leibovich Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
43. R. Hino, K. Kabashima, and Y. Kato Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 116 2010 1757 1766
44. J.M. Taube, R.A. Anders, and G.D. Young Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra137
45. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
46. J.R. Brahmer, C.G. Drake, and I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
47. Hodi F, Sznol M, Kluger H, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. In 2014 ASCO Annual Meeting; J Clin Oncol; abstract 9002; Chicago, IL; 2014.
48. O. Hamid, C. Robert, and A. Daud Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
49. Ribas A, Hodi F, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). In 2014 ASCO Annual Meeting; J Clin Oncol; abstract LBA9000; Chicago, IL; 2014.
50. R. Berger, R. Rotem-Yehudar, and G. Slama Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 2008 3044 3051
51. ClinicalTrials.gov [http://www.clinicaltrials.gov/ct2/results?term=CT-011+.]
52. Atkins M, Kudchadkar R, Sznol M, et al. Phase 2, multicenter, safety and efficacy study of pidlilizumab in patients with metastatic melanoma. In 2014 ASCO Annual Meeting; J Clin Oncol; abstract 9001; Chicago, IL; 2014.
53. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
54. R.S. Herbst, M.S. Gordon, and G.D. Fine A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors In J Clin Oncol 31 suppl; abstr 3000 2013
55. Fonsatti E, Maio M, Altomonte M, Hersey P. Biology and clinical applications of CD40 in cancer treatment. Semin Oncol. 20;37:517-23.
56. E.M. Sotomayor, I. Borrello, and E. Tubb Conversion of tumor-specific CD4+T-cell tolerance to T-cell priming through in vivo ligation of CD40 Nat Med 5 1999 780 787
57. L. Diehl, A.T. den Boer, and S.P. Schoenberger CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat Med 5 1999 774 779
58. P.Y. Pan, G. Ma, and K.J. Weber Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer Cancer Res 70 2010 99 108
59. G.J. van Mierlo, Z.F. Boonman, and H.M. Dumortier Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+CTL to cause tumor eradication J Immunol 173 2004 6753 6759
60. G.J. van Mierlo, A.T. den Boer, and J.P. Medema CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity Proc Natl Acad Sci U S A 99 2002 5561 5566
61. R.H. Vonderheide, K.T. Flaherty, and M. Khalil Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody J Clin Oncol 25 2007 876 883
62. J. Ruter, S.J. Antonia, H.A. Burris, R.D. Huhn, and R.H. Vonderheide Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors Cancer Biol Ther 10 2010 983 993
63. C.L. Law, K.A. Gordon, and J. Collier Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40 Cancer Res 65 2005 8331 8338
64. S. Khubchandani, M.S. Czuczman, and F.J. Hernandez-Ilizaliturri Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies Curr Opin Investig Drugs 10 2009 579 587
65. W.L. Redmond, M.J. Gough, B. Charbonneau, T.L. Ratliff, and A.D. Weinberg Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist J Immunol 179 2007 7244 7253
66. J. Kjaergaard, J. Tanaka, J.A. Kim, K. Rothchild, A. Weinberg, and S. Shu Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth Cancer Res 60 2000 5514 5521
67. D.E. Evans, R.A. Prell, C.J. Thalhofer, A.A. Hurwitz, and A.D. Weinberg Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4 J Immunol 167 2001 6804 6811
68. A.D. Weinberg, M.M. Rivera, and R. Prell Engagement of the OX-40 receptor in vivo enhances antitumor immunity J Immunol 164 2000 2160 2169
69. B. Curti, M. Kovacsovics-Bankowski, and N. Morris OX40 is a potent immune stimulating target in late stage cancer patients Cancer Res 73 24 2013 7189 7198
70. H. Zhang, K.M. Snyder, and M.M. Suhoski 4-1BB is superior to CD28 costimulation for generating CD8+cytotoxic lymphocytes for adoptive immunotherapy J Immunol 179 2007 4910 4918
71. R.E. Miller, J. Jones, and T. Le 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner J Immunol 169 2002 1792 1800
72. K.F. May Jr., L. Chen, P. Zheng, and Y. Liu Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+T cells Cancer Res 62 2002 3459 3465
73. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, Wojtaszek C, Feltquate D, Logan T. Phase I study of BMS-663513 a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol (Meeting Abstracts). 2008;26:3007.
74. ClinicalTrials.gov [http://www.clinicaltrials.gov/ct2/results]. September 3, 2009.
75. T. Tatsumi, L.S. Kierstead, and E. Ranieri Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma J Exp Med 196 2002 619 628
76. T. Nishimura, M. Nakui, and M. Sato The critical role of Th1-dominant immunity in tumor immunology Cancer Chemother Pharmacol 46 Suppl 2000 S52 S61
77. J.A. Carballido, L.M. Molto, L. Manzano, C. Olivier, O.J. Salmeron, and M. Alvarez de Mon Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder Cancer 72 1993 1743 1748
78. J.F. Brunet, F. Denizot, and M.F. Luciani A new member of the immunoglobulin superfamily - CTLA-4 Nature 328 1987 267 270
79. R. Khattri, J.A. Auger, M.D. Griffin, A.H. Sharpe, and J.A. Bluestone Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses J Immunol 162 1999 5784 5791
80. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
81. P. Waterhouse, J.M. Penninger, and E. Timms Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4 Science 270 1995 985 988
82. H. Lin, J.C. Rathmell, G.S. Gray, C.B. Thompson, J.M. Leiden, and M.L. Alegre Cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA-4 can function independently of CD28 J Exp Med 188 1998 199 204
83. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J Exp Med 182 1995 459 465
84. A.A. Hurwitz, B.A. Foster, and E.D. Kwon Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2000 2444 2448
85. E.D. Kwon, B.A. Foster, and A.A. Hurwitz Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy Proc Natl Acad Sci U S A 96 1999 15074 15079
86. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366
87. Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA-4 therapeutic antibody CP-675,206. In Proc Am Assoc Cancer Res. 2004;45:abstract 3802.
88. D.T. Ribas A, B. Comin-Anduix, and P. de la Rocha Changes in intratumoral immune cell infiltrates, Foxp3 and indoleamine 2, 3-dioxygenase (IDO) expression with the CTLA-4 blocking MAB CP-675,206 J Immunother 29 2006 636
89. S. Urbani, B. Amadei, and D. Tola PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion J Virol 80 2006 11398 11403
90. A.A. Tarhini, L.H. Butterfield, Y. Shuai, W.E. Gooding, P. Kalinski, and J.M. Kirkwood Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA-4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination J Immunother 35 2012 702 710
91. M. Ferrantini, I. Capone, and F. Belardelli Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use Biochimie 89 2007 884 893
92. J.M. Curtsinger, J.O. Valenzuela, P. Agarwal, D. Lins, and M.F. Mescher Type I. IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation J Immunol 174 2005 4465 4469
93. M.Y. Gerner, L.M. Heltemes-Harris, B.T. Fife, and M.F. Mescher Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control J Immunol 191 2013 1011 1015
94. J. Fourcade, P. Kudela, and Z. Sun PD-1 is a regulator of NY-ESO-1-specific CD8+T cell expansion in melanoma patients J Immunol 182 2009 5240 5249
95. M. Muhlbauer, M. Fleck, and C. Schutz PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis J Hepatol 45 2006 520 528